PANews reported on November 22 that according to PR Newswire, the U.S. listed company Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that its board of directors has approved the purchase of Bitcoin as a treasury reserve asset, aiming to diversify the company's assets while enabling Anixa to benefit from the potential long-term value of digital assets.
It is reported that Anixa is a clinical-stage biotechnology company focusing on cancer treatment and prevention.
